Eyeworld

PMS 355 CMYK 87, 16, 99, 3 PMS 376 CMYK 56, 3, 100, 0 PMS 292 CMYK 58, 14, 0, 0 60% PMS 292 CMYK 31, 9, 0, 0 Reach for ROCKLATAN ® for patients with open-angle glaucoma or ocular hypertension who are not at target pressure with a PGA. Visit ReachForROCKLATAN.com to learn more. THE ART OF LOWERING PRESSURE ONE DROP, ONE BOTTLE, ONCEDAILY © 2024 Alcon Inc. US-ROC-2400005 Because the next step in glaucoma care is as important as the fi rst. INDICATIONS AND USAGE: ROCKLATAN ® (netarsudil and latanoprost oph- thalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraoc- ular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION: CONTRAINDICATIONS: None. WARNINGS AND PRECAUTIONS: Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent. Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment. Use with caution in patients with a history of intraocular infl ammation (iritis uveitis). Should generally not be used in patients with active intraocular infl am- mation. Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema. Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis. Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients. Remove contact lenses prior to administration and reinsert 15 minutes after administration. ADVERSE REACTIONS: The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients. DOSAGE AND ADMINISTRATION: The recommended dosage is one drop in the aff ected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN ® should not exceed once daily. ROCKLATAN ® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least fi ve (5) minutes apart. Please see Brief Summary for ROCKLATAN ® Solution on the follow- ing page. To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

• Cover